ADVFN ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Hot Features

Icon for monitor Überwachen Sie mehrere Echtzeitkurse von führenden Börsen wie NASDAQ, NYSE, AMEX, Bovespa und mehr.
Gyre Therapeutics Inc

Gyre Therapeutics Inc (GYRE)

6,13
0,08
(1,32%)
Geschlossen 10 Juni 10:00PM
6,10
-0,03
(-0,49%)
Nach Börsenschluss: 1:59AM

Gyre Therapeutics Inc (GYRE) Aktie

Echtzeit-Diskussionen und Handelsideen: Handeln Sie mit Zuversicht mit unserer leistungsstarken Plattform.

Premium

Wichtige Statistiken und Details

Current Price
6,13
( 1,32% )
Gebot
5,93
Fragen
6,29
Volumen
92.648
5,93 Tagesbereich 6,19
5,44 52-Wochen-Bereich 9,42
Marktkapitalisierung
Handelsende
6,05
Handelsbeginn
6,05
Letzte Trade
1
@
6.01
Letzter Handelszeitpunkt
Finanzvolumen
US$ 564.029
VWAP
6,0879
Durchschnittliches Volumen (3 Mio.)
US$ 95.462
Ausgegebene Aktien
91.371.943
Dividendenrendite (LTM)
Kurs-Gewinn-Verhältnis
-82,53
Gewinn pro Aktie (EPS)
-0,08
Erlöse (LTM)
117,05M
Nettogewinn (LTM)
-6,36M

Über Gyre Therapeutics Inc

Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. The company offers ETUARY (Pirfenidone), an anti-fibrotic drug approved for the treatment of idiopathic pulmonar... Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. The company offers ETUARY (Pirfenidone), an anti-fibrotic drug approved for the treatment of idiopathic pulmonary fibrosis; and under Phase 3 trials for the treatment of pneumoconiosis. It is also involved in the development of F351 (Hydronidone), a structural derivative of ETUARY under Phase 3 trials for the treatment of chronic hepatitis B (CHB)-associated liver fibrosis; and completed Phase 1 trials for the treatment of liver fibrosis associated with metabolic dysfunction-associated steatohepatitis. In addition, the company develops F573, which is in Phase 2 clinical trials for the treatment of acute/acute-on-chronic liver failure. Further, its preclinical products include F230 for the treatment of pulmonary arterial hypertension; and F528 to treat chronic obstructive pulmonary disease. Gyre Therapeutics, Inc. was founded in 2002 and is headquartered in San Diego, California. Gyre Therapeutics, Inc. operates as a subsidiary of GNI USA, Inc. Mehr anzeigen

Sektor
Healthcare
Branche
Biotechnology & Life Sciences
Website
Hauptsitz
San Diego, United States
Gegründet
2026
Gyre Therapeutics Inc is listed in the Healthcare sector of the NASDAQ with ticker GYRE. The last closing price for Gyre Therapeutics was US$6,05. Over the last year, Gyre Therapeutics shares have traded in a share price range of US$ 5,44 to US$ 9,42.

Gyre Therapeutics currently has 91.371.943 shares in issue. The market capitalisation of Gyre Therapeutics is US$560,11 million. Gyre Therapeutics has a price to earnings ratio (PE ratio) of -82.53.

GYRE Neueste Nachrichten

Zeitraum †ÄnderungÄnderung %HandelsbeginnHochNiedrigDurchsch. VolumenVWAP
10.335.689655172415.86.665.441082445.98813722CS
4-0.9-12.80227596027.037.435.441009616.19840552CS
12-1.53-19.97389033947.668.25.44871376.87888585CS
26-1.99-24.50738916268.129.145.44872957.39343315CS
52-2.42-28.30409356738.559.425.44942047.5854203CS
156-0.87-12.4285714286730.45.4410199310.94164223CS
260-0.87-12.4285714286730.45.4410199310.94164223CS

GYRE - Frequently Asked Questions (FAQ)

What is the current Gyre Therapeutics Inc share price?
The current share price of Gyre Therapeutics Inc is US$ 6,13
How many Gyre Therapeutics Inc shares are in issue?
Gyre Therapeutics Inc has 91.371.943 shares in issue
What is the market cap of Gyre Therapeutics Inc?
The market capitalisation of Gyre Therapeutics Inc is USD 560,11M
What is the 1 year trading range for Gyre Therapeutics Inc share price?
Gyre Therapeutics Inc has traded in the range of US$ 5,44 to US$ 9,42 during the past year
What is the PE ratio of Gyre Therapeutics Inc?
The price to earnings ratio of Gyre Therapeutics Inc is -82,53
What is the cash to sales ratio of Gyre Therapeutics Inc?
The cash to sales ratio of Gyre Therapeutics Inc is 4,91
What is the registered address of Gyre Therapeutics Inc?
The registered address for Gyre Therapeutics Inc is 12730 High Bluff Drive, San Diego, California, 92130
What is the Gyre Therapeutics Inc website address?
The website address for Gyre Therapeutics Inc is www.gyretx.com
Which industry sector does Gyre Therapeutics Inc operate in?
Gyre Therapeutics Inc operates in the Biotechnology & Life Sciences sector

GYRE Trades

Mehr

Trades verzögert

Um Echtzeit-Trades zu erhalten, aktualisieren Sie Ihr Konto

Auf Echtzeit aktualisieren
Keine Diskussionen Gefunden.
Neuen Thread Erstellen